- Home
- PROP vs CTMX Comparison
PROP vs CTMX Comparison
Compare PROP & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PROP | CTMX |
|---|---|---|
| Founded | 2001 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.1M | 716.9M |
| IPO Year | 2008 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PROP | CTMX |
|---|---|---|
| Price | $0.40 | $2.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $2.00 | ★ $12.25 |
| AVG Volume (30 Days) | 995.4K | ★ 3.6M |
| Earning Date | 11-13-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,939,000.00 | ★ $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $92.07 | $1.24 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ 413.59 | N/A |
| 52 Week Low | $0.38 | $2.60 |
| 52 Week High | $2.55 | $8.21 |
Technical Indicators
Market Signals| Indicator | PROP | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 36.03 | 37.27 |
| Support Level | $0.38 | N/A |
| Resistance Level | $0.59 | $3.93 |
| Average True Range (ATR) | 0.03 | 0.18 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 18.56 | 17.11 |
Price Performance
Historical ComparisonAbout PROP Prairie Operating Co.
Prairie Operating Co is an independent oil and natural gas company focused on the acquisition and development of crude oil, natural gas, and natural gas liquids (NGLs). Its assets and operations are located in the oil region of rural Weld County, Colorado, within the Denver-Julesburg Basin in Colorado (the DJ Basin). The company generates maximum revenue from crude oil sales, and the rest from the sale of natural gas and natural gas liquids.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.